Canada’s Cannabis Bust: How Canopy Growth, Tilray and Aurora Burned Billions After Legalisation

Canada’s cannabis bust is the story of what happens when a brand-new legal market is priced for perfection before a single gram has been sold through a regulated store. Between 2017 and early 2019 investors poured tens of billions of dollars into Canadian licensed producers, led by Constellation Brands’ bet on Canopy Growth. The next five years brought write-downs that ran into the billions, a dozen chief executive changes and a wave of creditor-protection filings. This article explains how the boom was built, why it collapsed, what the industry looks like in October 2026 and which lessons apply to any founder or investor entering a newly legal market. It is part of the Canada Company Stories hub.

What did Canada actually legalise in October 2018?

Canada became the first G7 country to legalise recreational cannabis nationally when the Cannabis Act took effect on 17 October 2018, with edibles, beverages and extracts following a year later. The federal government licensed cultivation and processing through Health Canada, while provinces controlled wholesale distribution and retail, which produced thirteen different provincial and territorial systems and thirteen different excise stamps.

The policy goal was public health rather than industry growth: displace the illicit market, keep product away from minors and generate a modest tax take. That framing matters because it shaped the rules that later squeezed producers. Plain packaging, strict limits on marketing, THC caps on edibles and a per-gram excise duty were all designed for a world in which legal cannabis would sell at a premium, not one in which wholesale flower would fall below C$1 a gram within four years.

Investors read the same event very differently. Medical licensing since 2013 had already created a cohort of listed producers, and the promise of an open consumer market turned them into momentum stocks. By the autumn of 2018 the combined market value of Canadian producers was commonly estimated at more than C$50 billion, against annual legal sales that had not yet begun.

Why did Constellation Brands bet C$5 billion on Canopy Growth?

Constellation, the US owner of Corona and Modelo in the United States, saw cannabis as the next beverage-alcohol adjacency and chose Canopy as its vehicle. It took an initial stake in October 2017 and in August 2018 agreed to invest about C$5 billion (US$4 billion) for a holding of roughly 38 per cent plus warrants, the largest single investment the sector had ever seen.

The logic was that a global consumer-products company could professionalise a founder-led start-up, build cannabis-infused drinks and position itself for eventual US federal legalisation. Canopy’s co-founder and chief executive Bruce Linton used the money to buy greenhouses, European licences and US hemp assets, and to sign a conditional deal to acquire US operator Acreage Holdings once federal law allowed.

The partnership soured quickly. Constellation removed Linton in July 2019, installed its own finance chief David Klein as Canopy CEO in January 2020, and began a long programme of closing facilities. In October 2022 Constellation converted its common shares into exchangeable shares with no voting rights, deconsolidated Canopy and, in the same quarter, wrote the investment down by a little under US$1.1 billion. Canopy for its part booked a C$1.7 billion goodwill impairment that summer. Cumulatively, the lion’s share of the original C$5 billion has been written off.

How did Aurora and Tilray build empires that could not pay for themselves?

Aurora Cannabis, based in Edmonton, and Tilray, originally from Nanaimo, British Columbia, followed the same playbook of share-funded acquisitions. Aurora bought MedReleaf for about C$3.2 billion in stock in 2018 and CanniMed for roughly C$1.1 billion, building a theoretical capacity of hundreds of thousands of kilograms a year. Tilray listed on Nasdaq in July 2018, briefly traded above US$200 a share and in 2021 merged with Aphria, the larger of the two, in an all-share deal that kept the Tilray name under Aphria’s chief executive Irwin Simon.

Both companies assumed that scale would win. In practice, demand was capped by slow retail licensing, particularly in Ontario, where only 25 stores were open in the first year, and by a persistent illicit market selling at lower prices with higher potency. Oversupply forced producers to write down inventory, mothball greenhouses and dismiss thousands of staff. Aurora cut its workforce, closed facilities and executed a 1-for-12 reverse share split in 2020. Tilray, under Simon, began diversifying into craft beer and spirits in the United States, buying brands from Anheuser-Busch InBev and Molson Coors.

The common factor was that revenues never caught up with the capital base. Canopy’s net revenue in fiscal 2026 (year to March 2026) was C$284.6 million, a figure that would have looked modest to the analysts of 2018 who modelled billions.

What role did the excise tax and the illicit market play?

The federal excise duty on dried cannabis is the greater of C$1 per gram or 10 per cent of the producer’s selling price. When the duty was designed, policymakers assumed a retail price near C$10 a gram, making the two formulas roughly equivalent. As wholesale prices collapsed, the flat C$1 floor became the binding constraint, and in many cases excise came to represent 30 per cent or more of a producer’s net revenue.

The Cannabis Council of Canada, with support from a Deloitte study published in May 2025, has argued for capping the duty at 10 per cent of price and replacing the thirteen provincial stamps with one national stamp. The Standing Committee on Finance recommended an adjustment, and Ottawa said in late 2024 that it was exploring a single harmonised stamp. Yet Budget 2025, tabled on 4 November 2025, contained neither reform. Instead it cut the price ceiling for medical cannabis reimbursed through Veterans Affairs from C$8.50 to C$6.00 a gram, prompting Aurora’s Miguel Martin and Organigram’s Beena Goldenberg to say the government had missed an opportunity.

Unpaid excise has become a serious problem. Restructuring lawyers at Miller Thomson noted in 2025 that several producers were already insolvent and that cheaper imports from countries including Croatia had begun to depress prices further. Industry monitors counted three Canadian licence holders entering CCAA creditor protection in the first months of 2026 even as the country posted record export volumes.

How has Canopy Growth rebuilt its balance sheet under Luc Mongeau?

Canopy’s turnaround under chief executive Luc Mongeau, who took over in January 2025, has rested on shrinking debt, concentrating on medical cannabis and buying growth selectively. On 8 January 2026 the company announced a recapitalisation: a US$150 million net-proceeds term loan led by JGB Management maturing in January 2031, repayment of about US$101 million of senior secured debt due September 2027, and an exchange of about C$96.4 million of 2029 convertible debentures for C$55 million of new 7.5 per cent debentures due 2031, cash, shares and warrants. Pro forma cash was about C$425 million and every maturity was pushed out to 2031 at the earliest.

In March 2026 Canopy completed the C$125 million acquisition of MTL Cannabis, a Quebec producer with its own clinics, patient network and the ABBA Medix online channel. Canopy says the combination makes it Canada’s largest medical cannabis business by revenue, and MTL’s former chief executive Michael Perron became Canopy’s chief operating officer.

The fiscal 2026 results published on 15 June 2026 show how far the business has been cut back and how far it still has to go. Net revenue was C$284.6 million, up 6 per cent; the net loss from continuing operations narrowed 49 per cent to C$262.9 million; adjusted EBITDA was a loss of C$20.2 million; and free cash outflow fell to C$69.1 million from C$176.6 million. Cash of C$364.7 million against debt of about C$233.4 million left net cash of C$131.3 million, compared with net debt of C$172.6 million a year earlier. Management expects positive adjusted EBITDA during fiscal 2027, and first-quarter fiscal 2027 revenue grew 13 per cent. The cost was heavy dilution: shares outstanding multiplied through the recapitalisation and prior equity raises.

Why has Tilray stopped calling itself a cannabis company?

Tilray’s answer to the Canadian squeeze was to become something else. Under Irwin Simon the company assembled a portfolio of more than twenty craft beer, spirits and wellness brands, mostly in the United States, and in March 2026 added BrewDog’s UK brewing operations and eleven pubs for £33 million, a deal followed by the closure of 38 BrewDog pubs and 484 job cuts in a restructuring.

The fiscal 2026 results reported on 29 July 2026 were a record: net revenue of US$915.5 million, up 11 per cent, gross profit of US$260.4 million and adjusted EBITDA of US$61.1 million. Beverage revenue reached US$254 million, with fourth-quarter beverage sales up 61 per cent. For fiscal 2027 the company guided to revenue above US$1 billion and adjusted EBITDA of US$68 million to US$75 million. Cannabis remains the largest segment by revenue and Tilray is still the leading Canadian producer by share in several provinces, but the equity story is now about diversification and cash generation rather than plant count.

That pivot has its critics. Beer is a mature, low-growth category and Tilray’s alcohol brands were acquired largely because the sellers wanted out. Yet the strategy has kept Tilray listed on Nasdaq, funded with modest leverage and able to report positive adjusted EBITDA, which is more than most Canadian peers of 2018 can say.

Why is Curaleaf trying to buy Aurora, and why is Aurora saying no?

Curaleaf, the largest US multistate operator by revenue, launched an unsolicited bid for Aurora in August 2026 at about US$4.00 a share, a 45 per cent premium to Aurora’s 30-day average, structured as US$0.75 in cash plus 0.3463 Curaleaf shares. On 5 October 2026 it raised the headline value to US$5.00 a share, implying roughly US$272 million for the company. Aurora’s board, led by chief executive Miguel Martin, has twice urged shareholders to reject the offer, most recently on 14 October 2026.

Aurora’s case is that it is debt-free apart from lease liabilities, profitable in its medical business in Canada, Germany, Australia and Poland, and would be exchanging a clean balance sheet for paper in a company carrying nearly US$1 billion of debt. The board says it is evaluating strategic alternatives with multiple parties and has reportedly held talks with Organigram, the Moncton producer part-owned by British American Tobacco. Curaleaf founder Boris Jordan has accused Aurora of refusing due-diligence access; the bid is open until December.

The episode shows what has changed since 2018. US operators once needed Canadian listings for capital; now a US company with real cash flow is using its shares to buy Canadian international distribution. The Canadian asset of greatest value turns out to be export licences and German medical market share, not domestic recreational brands.

What does US rescheduling to Schedule III mean for Canadian producers?

The United States moved FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act through a Department of Justice order signed on 23 April 2026 and effective from 28 April 2026. The practical effect is to lift Section 280E of the tax code from state-legal operators, which investors estimate cuts their effective tax rate from about 70 per cent to roughly the 21 per cent corporate rate, and to open the door to exchange listings for US operators.

Rescheduling does not legalise interstate commerce or imports, so Canadian producers cannot simply ship flower to Illinois. What it does is make US operators richer and more acquisitive, which is exactly the dynamic playing out in Curaleaf’s bid for Aurora. Canopy’s structure anticipated this: its non-controlling interest in Canopy USA, which holds Acreage, Wana and Jetty, was designed to give Canadian shareholders exposure to US THC without breaching exchange rules. Whether that optionality is worth much now depends on how quickly the DEA registration process and the stalled federal banking and listing reforms move.

For Canadian policymakers the US shift sharpens the competitive problem: a producer in Ontario paying C$1 a gram in excise competes for capital with a Florida operator whose tax bill has just been cut by two-thirds.

Where are the growth markets for Canadian cannabis now?

Exports and medical cannabis are carrying the industry. Canada exported about 275 tonnes in 2025, up 143 per cent on the previous year, and most of that flower went to Germany after its partial legalisation in April 2024 removed the narcotics classification and simplified prescriptions. Australia, Poland and the UK also take Canadian product, and Canopy reported 68 per cent growth in international cannabis revenue in its fourth quarter of fiscal 2026.

Domestically, medical cannabis has become the profitable niche. Canopy’s Canadian medical revenue rose 27 per cent in the same quarter, and the MTL acquisition was explicitly a medical play. Recreational flower, by contrast, has turned into a commodity in which value brands with high THC per dollar dominate and the leading share positions change every quarter.

The retail layer has stabilised at roughly 3,500 to 4,000 stores nationally, with Ontario the largest market and provinces experimenting with longer hours; Ontario extended retail trading to 7am-11pm from May 2026. Health Canada’s March 2025 streamlining of licensing, security and packaging rules modestly lowered compliance cost. The overdue statutory review of the Cannabis Act and a pending decision on on-premise consumption of beverages are the next regulatory catalysts.

What can founders and investors learn from the cannabis bust?

The first lesson is that capacity is not a moat. Every major producer believed that being the largest grower would secure shelf space and pricing power; instead, excess capacity across the sector collapsed prices for everyone, and the companies that survived were those that closed greenhouses fastest. Scarcity of licences lasted eighteen months; scarcity of customers lasted years.

The second lesson concerns strategic investors. Constellation’s capital allowed Canopy to outspend rivals, but it also removed the discipline that a cash-constrained start-up would have faced, and the governance friction between a founder-CEO and a 38 per cent shareholder ended in the founder’s exit within a year. Founders raising from a corporate investor should negotiate operating autonomy and exit terms before the money lands, a theme that also runs through Couche-Tard’s pursuit of Seven & i, where a Canadian buyer learned how much board control is worth.

The third lesson is about taxes and regulation as business inputs. The excise regime was a known parameter in 2018; the error was assuming it would be reformed when prices fell. Investors should price the regulatory status quo, not the promised reform. The Canadian banking oligopoly is the mirror image: a regulated structure that protects incumbents’ margins rather than squeezing them, and investors who assumed that structure would persist have been rewarded.

Finally, the stories of AbCellera and Vancouver’s biotech cluster and of Bausch Health’s Valeant legacy show two other Canadian life-sciences businesses that discovered, in different ways, the gap between a market narrative and durable cash flow. Cannabis simply compressed that cycle into five years. For comparison, the Australia Company Stories hub covers a medical-cannabis market that grew more slowly, with far less capital destroyed.

Frequently Asked Questions